SVA (Sinovac Biotech) ROE % Adjusted to Book Value: -26.90% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SVA Sinovac Biotech Ltd SVA
12 GF Score
Price $6.47
! 9 Warning Signs
View Full Analysis

What is Sinovac Biotech ROE % Adjusted to Book Value?

Sinovac Biotech SVA 12 ROE % Adjusted to Book Value is -26.90% as of Jun. 2026. GuruFocus rates SVA with a GF Score™ of 12/100. The stock has 9 warning signs investors should review.

Sinovac Biotech's ROE % for the quarter that ended in Jun. 2026 was -2.69%. Sinovac Biotech's PB Ratio for the quarter that ended in Jun. 2026 was 0.10. Sinovac Biotech's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2026 was -26.90%.

Sinovac Biotech ROE % Adjusted to Book Value Related Terms

Sinovac Biotech ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Sinovac Biotech's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinovac Biotech ROE % Adjusted to Book Value Chart

Sinovac Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,401.57 17.86 -3.00 17.83 -9.40

Sinovac Biotech Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.20 -1.17 -6.27 -17.30 -26.90

SVA vs INBX, HLVX, KOD: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Sinovac Biotech's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sinovac Biotech ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sinovac Biotech's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Sinovac Biotech's ROE % Adjusted to Book Value falls into.


SVA
12GF Score
Sinovac Biotech Ltd SVA
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinovac Biotech ROE % Adjusted to Book Value Calculation

Sinovac Biotech's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-0.94% / 0.10
=-9.40%

Sinovac Biotech's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-2.69% / 0.10
=-26.90%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -26.90% mean?
Sinovac Biotech (SVA) has a ROE % Adjusted to Book Value of -26.90% as of Jun. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Sinovac Biotech and its competitors.
Is Sinovac Biotech's ROE % Adjusted to Book Value too high?
Sinovac Biotech's current ROE % Adjusted to Book Value is -26.90%. Overall, Sinovac Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sinovac Biotech's ROE % Adjusted to Book Value compare to INBX and HLVX?
Sinovac Biotech's ROE % Adjusted to Book Value of -26.90% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Sinovac Biotech and its competitors. Sinovac Biotech's current ROE % Adjusted to Book Value is -26.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinovac Biotech stock overvalued right now?
Sinovac Biotech (SVA) has a current ROE % Adjusted to Book Value of -26.90%. The current ROE % Adjusted to Book Value is -26.90%. Sinovac Biotech's overall GF Score™ is 12/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Sinovac Biotech (SVA), the current ROE % Adjusted to Book Value is -26.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sinovac Biotech Business Description

Address No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085
Sinovac Biotech Ltd is a fully integrated China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of vaccines for the prevention of human infectious diseases, including certain diseases with unmet medical needs. It has developed a comprehensive vaccine portfolio covering hepatitis A, hepatitis B, hand, foot and mouth disease ("HFMD") caused by enterovirus 71 ("EV71"), seasonal and pandemic influenza, COVID-19, pneumococcal disease, poliomyelitis, mumps, varicella, rabies and tetanus. The Company operates exclusively in the research, development, manufacture, and commercialization of vaccines sector. The Company's business is considered as operating in one segment. It has presence in Chinese Mainland, and Outside Chinese Mainland.
12GF Score

Get the complete analysis for SVA

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.47
Price